AstraZeneca could pay £255m for ‘defective’ Covid vaccine
AstraZeneca could pay £255m for ‘defective’ Covid vaccine after admitting it can cause rare blood clot side effect.
AstraZeneca might have to pay up to £255 million in compensation because their Covid vaccine has been found to cause a very rare blood clot side effect, DailyMail reported.
More than £250 million could be awarded to those who claim they’ve been harmed by AstraZeneca’s Covid vaccine, according to court documents.
According to DailyMail, 51 cases have been filed in London’s High Court. Lawyers representing the victims and families are suing AstraZeneca under the Consumer Protection Act 1987.
They argue the vaccine was ‘a defective product’ that was ‘not as safe as consumers generally were reasonably entitled to expect’.
The families say that the AstraZeneca jab caused injuries and even deaths among their loved ones.
AstraZeneca has strongly denied these claims.
The pharmaceutical company admitted in a legal document from February that its vaccine can “in very rare cases” lead to a condition known as thrombosis with thrombocytopenia syndrome (TTS), The condition is also known as vaccine-induced immune thrombotic thrombocytopenia (VITT).
TTS can lead to blood clots and a low count of blood platelets, and in some cases, it has seriously harmed or even caused the deaths of people who received AstraZeneca’s vaccine.
The possibility of TTS has been noted as a potential side effect since the vaccine’s launch. But AstraZeneca’s statement in February was the first time the company admitted it in court, according to The Telegraph.
TTS is believed to be connected to at least 81 deaths in the UK.
However, not all these cases have been conclusively proven, and not every family is pursuing legal action, DailyMail reported.
